AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma | |
Leonard, John P.; Trneny, Marek; Izutsu, Koji; Fowler, Nathan H.; Hong, Xiaonan; Zhu, Jun; Zhang, Huilai; Offner, Fritz; Scheliga, Adriana; Nowakowski, Grzegorz S. | |
刊名 | JOURNAL OF CLINICAL ONCOLOGY |
2019 | |
卷号 | 37期号:14 |
ISSN号 | 0732-183X |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3598542 |
专题 | 复旦大学上海医学院 |
推荐引用方式 GB/T 7714 | Leonard, John P.,Trneny, Marek,Izutsu, Koji,et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma[J]. JOURNAL OF CLINICAL ONCOLOGY,2019,37(14). |
APA | Leonard, John P..,Trneny, Marek.,Izutsu, Koji.,Fowler, Nathan H..,Hong, Xiaonan.,...&Kern, Julie.(2019).AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.JOURNAL OF CLINICAL ONCOLOGY,37(14). |
MLA | Leonard, John P.,et al."AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma".JOURNAL OF CLINICAL ONCOLOGY 37.14(2019). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论